Zydus Cadila gets US Food and Drug Administration nod for diabetes medication
On October 31, 2020, Zydus had filed a new drug application (NDA) with the USFDA seeking approval to market Sitagliptin base 25, 50 and 100 mg tablets. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 6, 2021 Category: Pharmaceuticals Source Type: news
Diabetes drug may help women who have repeated miscarriages – study
Type of stem cell deficiency is common among women who lose pregnancies, and sitagliptin may helpA common diabetes drug may be able to help women who have repeated miscarriages, researchers have found, after they identified that a certain type of stem cell deficiency is common among women who lose pregnancies.A study for the Tommy ’s National Miscarriage Research Centre in London discovered that the diabetes drugsitagliptin can boost recruitment of these cells to the lining of the uterus, called the endometrium, in women who have experienced repeated miscarriages.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 25, 2021 Category: Science Authors: Linda Geddes Tags: Miscarriage Medical research Stem cells Biology Science Society Source Type: news
Sitagliptin Promising Addition for Preventing Acute GVHD
Low incidence of grade II to IV acute GVHD seen in patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 7, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Journal, Source Type: news
Sitagliptin Promising Addition for Preventing Acute GVHD
THURSDAY, Jan. 7, 2020 -- For patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation, sitagliptin combined with tacrolimus and sirolimus results in a low incidence of grade II to IV acute graft-versus-host disease... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 7, 2021 Category: Pharmaceuticals Source Type: news
New studies show diabetes drug not proven to improve blood sugar control in pediatric patients
The FDA has approved labeling changes stating that Januvia (sitagliptin), Janumet (sitagliptin and metformin hydrochloride), and Janumet XR (sitagliptin and metformin hydrochloride extended-release) are not proven to improve glycemic (blood sugar) control in pediatric patients. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 4, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Sitagliptin May Cut Mortality in T2DM Patients With COVID - 19
Sitagliptin at time of hospitalization linked to reduced mortality, improved clinical outcomes (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 14, 2020 Category: Respiratory Medicine Tags: Endocrinology, Family Medicine, Geriatrics, Infections, Internal Medicine, Critical Care, Emergency Medicine, Pharmacy, Pulmonology, Journal, Source Type: news
Sitagliptin May Cut Mortality in T2DM Patients With COVID-19
WEDNESDAY, Oct. 14, 2020 -- Sitagliptin treatment added to standard care is associated with reduced mortality and improved clinical outcomes for patients with type 2 diabetes hospitalized with COVID-19, according to a study published online Sept. 29... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 14, 2020 Category: Pharmaceuticals Source Type: news
Fewer Deaths in Hospitalized COVID Diabetes Patients on Sitagliptin Fewer Deaths in Hospitalized COVID Diabetes Patients on Sitagliptin
An observational, retrospective analysis of 338 patients with type 2 diabetes hospitalized for COVID-19 showed substantially less mortality among sitagliptin recipients compared with those on insulin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 1, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
(Boston Children's Hospital) Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy. Patients given sitagliptin in addition to insulin had a mortality rate of 18 percent as compared with 37 percent in matched patients receiving only insulin. Led by Paolo Fiorina, MD, PhD, of Boston Children's Hospital, the study involved seven Italian hospitals during the first surge of COVID cases last spring. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - September 29, 2020 Category: Infectious Diseases Source Type: news
Sitagliptin Decreases Visceral Fat and Blood Glucose in PCOS Sitagliptin Decreases Visceral Fat and Blood Glucose in PCOS
What benefits might the DPP-4 inhibitor sitagliptin offer to women with PCOS?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - January 31, 2020 Category: Radiology Tags: Diabetes & Endocrinology Journal Article Source Type: news
Hope for women who endure recurrent miscarriages as 'diabetes drug boosts their womb lining'
If the drug, called sitagliptin, is successful in clinical trials, it would be one of very few treatment options for women who have tragically lost multiple babies, the University of Warwick said. (Source: the Mail online | Health)
Source: the Mail online | Health - January 9, 2020 Category: Consumer Health News Source Type: news
metformin and sitagliptin (Janumet)
Title: metformin and sitagliptin (Janumet)Category: MedicationsCreated: 7/28/2010 12:00:00 AMLast Editorial Review: 7/3/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - July 3, 2019 Category: Endocrinology Source Type: news
sitagliptin (Januvia)
Title: sitagliptin (Januvia)Category: MedicationsCreated: 4/25/2007 12:00:00 AMLast Editorial Review: 6/28/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - June 28, 2019 Category: Endocrinology Source Type: news
Little Difference With Oral Semaglutide vs Liraglutide in Diabetes Little Difference With Oral Semaglutide vs Liraglutide in Diabetes
PIONEER 4 trial shows noninferiority of oral semaglutide to liraglutide for HbA1c lowering, while PIONEER 7 shows superior glycemic control and weight loss compared with the DPP-4 inhibitor sitagliptin.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 11, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
PIONEER-3: Oral Semaglutide Shows Benefit in Type 2 Diabetes PIONEER-3: Oral Semaglutide Shows Benefit in Type 2 Diabetes
Higher doses of oral semaglutide reduce HbA1c better than sitagliptin in type 2 diabetes but has more gastrointestinal side effects. NDAs for the product have just been filed in the US.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - March 27, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
